# Combinatorial Drug Discovery Program Libraries

## Overview of Libraries

The Combinatorial Drug Discovery Program (CDDP) at GCC offers a variety of compound libraries to facilitate drug discovery and development. These libraries contain bioactive molecules, investigational agents, and FDA-approved drugs, arranged in formats suitable for high-throughput screening (HTS) and high content screening (HCS).

### Available Libraries

1. **CDDP Custom Informer (CCI)**
   - **Year**: 2022
   - **Number of Compounds**: 4,309
   - **Description**: The CCI library is a curated selection of 4,309 bioactive molecules from the MedChemExpress bioactive collection. It represents diverse chemical entities from clusters based on drug target and mechanism of action (MoA) annotations. This library provides high mechanistic coverage with relatively few molecules, balancing mechanistic probes with translational applications. The library is pre-arrayed in a 384-well plate format, facilitating efficient screening with enriched drug MoA coverage. All compounds are provided at 10 mM in DMSO.

2. **National Cancer Institute Approved Oncology Set XI**
   - **Year**: 2023
   - **Number of Compounds**: 180
   - **Description**: This set contains the most current FDA-approved anticancer drugs. It supports cancer research, drug discovery, and combination drug studies. All proprietary agents in this set were obtained through commercial sources and are supplied at 10 mM in DMSO. This collection is intended to enable cancer research by providing well-characterized drugs for use in screening and combination studies.

3. **TargetMol Epigenetics Compound Library**
   - **Year**: 2019
   - **Number of Compounds**: 380
   - **Description**: Contains compounds for studying epigenetic modifications, such as DNA methylation, histone modification, and RNA transcription. Epigenetics plays a critical role in regulating gene expression without altering the DNA sequence. This library is useful for investigating the role of epigenetics in diseases like cancer, aging, heart disease, and neurological disorders. Compounds are available at 10 mM in DMSO, suitable for both HTS and HCS applications.

4. **Custom Clinical Collection**
   - **Year**: 2021
   - **Number of Compounds**: 146
   - **Description**: Contains approximately 147 compounds targeting a variety of disease areas. Fifty-seven percent of the compounds are currently used in the clinic for the treatment of various cancers, while 37% are in clinical trials. This collection is pre-arrayed in 384-well plate format, allowing easy integration into screening workflows. Compounds are at 10 mM in DMSO.

### Targeted and Focused Libraries

1. **Cancer Therapy Evaluation Program (CTEP) Collection**
   - **Year**: 2018
   - **Number of Compounds**: 48
   - **Description**: This collection contains 48 drugs selected from the Cancer Therapy Evaluation Program (CTEP) investigational drug portfolio program of the National Cancer Institute (NCI). These compounds are part of the clinical therapeutics development program, focused on investigating new treatments for cancer. Compounds are provided at 10 mM in DMSO.

2. **TargetMol Mitochondrial Targeting Collection**
   - **Year**: 2019
   - **Number of Compounds**: 64
   - **Description**: A collection focusing on compounds that target mitochondrial functions, such as oxidative phosphorylation, calcium homeostasis, and reactive oxygen species (ROS) signaling. This library is useful for researching metabolic diseases, neurodegeneration, apoptosis, and hyperproliferative diseases such as cancer. Compounds are available at 10 mM in DMSO.

3. **TargetMol Wnt-Hedgehog-Notch Compound Library**
   - **Year**: 2019
   - **Number of Compounds**: 74
   - **Description**: Targets key signaling pathways involved in development and cancer, including Wnt, Hedgehog, and Notch pathways. These pathways are critical regulators of cell proliferation, differentiation, and tissue homeostasis. Aberrant signaling in these pathways is associated with cancer and other developmental disorders. Compounds are supplied at 10 mM in DMSO.

4. **TargetMol Oxidation-Reduction Compound Library**
   - **Year**: 2019
   - **Number of Compounds**: 118
   - **Description**: This library contains compounds that modulate oxidative stress pathways, including antioxidants and redox modulators. It is useful for exploring cancer cell vulnerabilities related to oxidative stress and studying the role of ROS in various diseases. Compounds are provided at 10 mM in DMSO.

5. **TargetMol Cell Cycle Related Compound Library**
   - **Year**: 2019
   - **Number of Compounds**: 130
   - **Description**: Contains compounds that target various stages of the cell cycle, such as CDK inhibitors and other agents that interfere with cell cycle progression. This library is applicable for cancer research, particularly in identifying compounds that induce cell cycle arrest or apoptosis. Compounds are available at 10 mM in DMSO.

- **TargetMol MAPK Inhibitor Library** (140 Compounds, 2019): Focuses on MAPK signaling pathways involved in cellular processes such as proliferation, differentiation, and stress response. Compounds target key kinases like ERK, JNK, and p38, which are implicated in cancer and inflammatory diseases. Compounds are at 10 mM in DMSO.

- **TargetMol JAK STAT Compound Library** (145 Compounds, 2019): Contains compounds targeting the JAK/STAT signaling pathway, which plays a key role in immune response, inflammation, and cancer. Compounds are suitable for HTS and HCS applications at 10 mM in DMSO.

- **TargetMol PI3K-AKT-mTOR Compound Library** (190 Compounds, 2019): Useful for studying the PI3K/AKT/mTOR signaling pathway, which is crucial in cell cycle regulation, cancer progression, and metabolic disorders. Compounds are available at 10 mM in DMSO.

- **TargetMol Apoptosis Compound Library** (191 Compounds, 2019): Focuses on compounds that regulate apoptosis, including pro-apoptotic and anti-apoptotic agents. This library is applicable for cancer and neurodegenerative disease research. Compounds are at 10 mM in DMSO.

- **TargetMol Endocrinology-Hormones Library** (297 Compounds, 2019): Targets pathways involved in endocrine regulation, including hormone synthesis and receptor signaling. This library is useful for studying metabolic disorders, growth regulation, and reproductive health. Compounds are supplied at 10 mM in DMSO.

- **TargetMol Tyrosine Kinase Inhibitor Library** (339 Compounds, 2019): Contains inhibitors for tyrosine kinases, which are important drug targets in cancer therapy. The library includes compounds targeting various tyrosine kinases involved in cell signaling and tumor progression. Compounds are at 10 mM in DMSO.

- **TargetMol Stem Cell Library** (340 Compounds, 2019): Useful for stem cell differentiation research. This library includes compounds that promote or inhibit differentiation of stem cells into various lineages. Compounds are available at 10 mM in DMSO.

- **TargetMol DNA Damage/Repair Compound Library** (475 Compounds, 2019): Focuses on compounds that modulate DNA repair pathways. This library is useful for studying the mechanisms of DNA damage response and identifying potential cancer therapeutics. Compounds are provided at 10 mM in DMSO.

- **TargetMol Fluorochemical Library** (586 Compounds, 2019): Contains fluorinated compounds that are used to improve bioavailability, metabolic stability, and binding affinity of drugs. These compounds have applications in cancer, infectious diseases, and CNS disorders. Compounds are supplied at 10 mM in DMSO.
  
- **TargetMol Ion Channel Inhibitor Library** (362 Compounds, 2019): Focuses on compounds that modulate ion channels, which are critical for cell communication and are implicated in diseases like epilepsy, cardiovascular disorders, and pain. Compounds are available at 10 mM in DMSO.

- **GPCR Collection** (353 Compounds, 2017): Targets G-protein coupled receptors (GPCRs), which are involved in numerous physiological processes and are important drug targets for a wide range of diseases. This library is suitable for GPCR screening and drug discovery projects. Compounds are at 10 mM in DMSO.

- **Broad Collection** (358 Compounds, 2021): Contains compounds from the “Informer Set” for cancer research. This collection includes compounds that target a wide range of cellular pathways relevant to cancer cell growth and survival. Compounds are at 10 mM in DMSO.

